Top

Published in:

01-06-2016 | Epidemiology

Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer

Authors: Lu Chen, Linda S. Cook, Mei-Tzu C. Tang, Peggy L. Porter, Deirdre A. Hill, Charles L. Wiggins, Christopher I. Li

Published in: Breast Cancer Research and Treatment | Issue 3/2016

Abstract

Triple negative (TN, tumors that do not express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth factor receptor 2 (HER2)) and HER2-overexpressing (H2E, ER−/HER2+) tumors are two particularly aggressive subtypes of breast cancer. There is a lack of knowledge regarding the etiologies of these cancers and in particular how anthropometric factors are related to risk. We conducted a population-based case–case study consisting of 2659 women aged 20–69 years diagnosed with invasive breast cancer from 2004 to 2012. Four case groups defined based on joint ER/PR/HER2 status were included: TN, H2E, luminal A (ER+/HER2−), and luminal B (ER+/HER2+). Polytomous logistic regression was used to estimate odds ratios (ORs) and associated 95 % confidence intervals (CIs) where luminal A patients served as the reference group. Obese premenopausal women [body mass index (BMI) ≥30 kg/m²] had an 82 % (95 % CI 1.32–2.51) increased risk of TN breast cancer compared to women whose BMI <25 kg/m², and those in the highest weight quartile (quartiles were categorized based on the distribution among luminal A patients) had a 79 % (95 % CI 1.23–2.64) increased risk of TN disease compared to those in the lowest quartile. Among postmenopausal women obesity was associated with reduced risks of both TN (OR = 0.74, 95 % CI 0.54–1.00) and H2E (OR = 0.47, 95 % CI 0.32–0.69) cancers. Our results suggest obesity has divergent impacts on risk of aggressive subtypes of breast cancer in premenopausal versus postmenopausal women, which may contribute to the higher incidence rates of TN cancers observed among younger African American and Hispanic women.

Perou CM, Sørlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752. doi:10.1038/35021093 CrossRefPubMed

Sørlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869–10874. doi:10.1073/pnas.191367098 CrossRefPubMedPubMedCentral

Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502. doi:10.1001/jama.295.21.2492 CrossRefPubMed

Onitilo AA, Engel JM, Greenlee RT, Mukesh BN (2009) Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 7:4–13. doi:10.3121/cmr.2009.825 CrossRefPubMedPubMedCentral

Dawood S, Hu R, Homes MD et al (2011) Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Res Treat 126:185–192. doi:10.1007/s10549-010-1113-7 CrossRefPubMed

Parise CA, Bauer KR, Brown MM, Caggiano V (2009) Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J 15:593–602. doi:10.1111/j.1524-4741.2009.00822.x CrossRefPubMed

Trentham-Dietz A, Newcomb PA, Storer BE et al (1997) Body size and risk of breast cancer. Am J Epidemiol 145:1011–1019. doi:10.1093/oxfordjournals.aje.a009057 CrossRefPubMed

Morimoto L, White E, Chen Z et al (2002) Obesity, body size, and risk of postmenopausal breast cancer: the Women’s Health Initiative (United States). Cancer Causes Control 13:741–751. doi:10.1023/A:1020239211145 CrossRefPubMed

van den Brandt PA, Spiegelman D, Yaun SS et al (2000) Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 152:514–527. doi:10.1093/aje/152.6.514 CrossRefPubMed

10.

Ursin G, Longnecker MP, Haile RW, Greenland S (1995) A meta-analysis of body mass index and risk of premenopausal breast cancer on JSTOR. Epidemiology 6:137–141CrossRefPubMed

11.

Horn J, Alsaker MDK, Opdahl S et al (2014) Anthropometric factors and risk of molecular breast cancer subtypes among postmenopausal Norwegian women. Int J Cancer 135:2678–2686. doi:10.1002/ijc.28912 CrossRefPubMed

12.

Yang XR, Sherman ME, Rimm DL et al (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomark Prev 16:439–443. doi:10.1158/1055-9965.EPI-06-0806 CrossRef

13.

Bandera EV, Chandran U, Hong C-C et al (2015) Obesity, body fat distribution, and risk of breast cancer subtypes in African American women participating in the AMBER Consortium. Breast Cancer Res Treat 150:655–666. doi:10.1007/s10549-015-3353-z CrossRefPubMedPubMedCentral

14.

Phipps AI, Malone KE, Porter PL et al (2008) Body size and risk of luminal, HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomark Prev 17:2078–2086. doi:10.1158/1055-9965.EPI-08-0206 CrossRef

15.

Gaudet MM, Press MF, Haile RW et al (2011) Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat 130:587–597. doi:10.1007/s10549-011-1616-x CrossRefPubMedPubMedCentral

16.

Kwan ML, Kushi LH, Weltzien E et al (2009) Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 11:R31. doi:10.1186/bcr2261 CrossRefPubMedPubMedCentral

17.

Millikan RC, Newman B, Tse CK et al (2008) Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 109:123–139. doi:10.1007/s10549-007-9632-6 CrossRefPubMed

18.

Dolle JM, Daling JR, White E et al (2009) Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomark Prev 18:1157–1166. doi:10.1158/1055-9965.EPI-08-1005 CrossRef

19.

Bauer KR, Brown M, Cress RD et al (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728. doi:10.1002/cncr.22618 CrossRefPubMed

20.

Li CI, Beaber EF, Tang MTC et al (2012) Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44 years of age. Cancer Res 72:2028–2035. doi:10.1158/0008-5472.CAN-11-4064 CrossRefPubMedPubMedCentral

21.

Li CI, Malone KE, Porter PL et al (2008) Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas. Cancer Epidemiol Biomark Prev 17:43–50. doi:10.1158/1055-9965.EPI-07-0558 CrossRef

22.

Munsell MF, Sprague BL, Berry DA et al (2014) Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status. Epidemiol Rev 36:114–136. doi:10.1093/epirev/mxt010 CrossRefPubMedPubMedCentral

23.

Key TJ, Appleby PN, Reeves GK et al (2003) Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst 95:1218–1226. doi:10.1093/jnci/djg022 CrossRefPubMed

24.

Tchernof A, Després JP (1999) Sex steroid hormones, sex hormone-binding globulin, and obesity in men and women. Horm Metab Res 32:526–536. doi:10.1055/s-2007-978681 CrossRef

25.

Schmidt ME, Steindorf K, Mutschelknauss E et al (2008) Physical activity and postmenopausal breast cancer: effect modification by breast cancer subtypes and effective periods in life. Cancer Epidemiol Biomark Prev 17:3402–3410. doi:10.1158/1055-9965.EPI-08-0479 CrossRef

26.

Steindorf K, Ritte R, Eomois P-P et al (2013) Physical activity and risk of breast cancer overall and by hormone receptor status: the European prospective investigation into cancer and nutrition. Int J Cancer 132:1667–1678. doi:10.1002/ijc.27778 CrossRefPubMed

27.

Phipps AI, Chlebowski RT, Prentice R et al (2011) Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomark Prev 20:454–463. doi:10.1158/1055-9965.EPI-10-0974 CrossRef

28.

Fournier A, Dos Santos G, Guillas G et al (2014) Recent recreational physical activity and breast cancer risk in postmenopausal women in the E3N cohort. Cancer Epidemiol Biomark Prev 23:1893–1902. doi:10.1158/1055-9965.EPI-14-0150 CrossRef

29.

Zhang X, Eliassen AH, Tamimi RM et al (2015) Adult body size and physical activity in relation to risk of breast cancer according to tumor androgen receptor status. Cancer Epidemiol Biomark Prev 24:962–968. doi:10.1158/1055-9965.EPI-14-1429 CrossRef

30.

Enger S, Ross R, Paganini-Hill A et al (2000) Body size, physical activity, and breast cancer hormone receptor status: Results from two case-control studies. Cancer Epidemiol Biomark Prev 9:681

31.

Lahmann PH, Hoffmann K, Allen N et al (2004) Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer And Nutrition (EPIC). Int J Cancer 111:762–771. doi:10.1002/ijc.20315 CrossRefPubMed

32.

Huang Z, Hankinson SE, Colditz GA et al (1997) Dual effects of weight and weight gain on breast cancer risk. JAMA 278:1407–1411CrossRefPubMed

33.

Kato I, Toniolo P, Koenig KL et al (1999) Epidemiologic correlates with menstrual cycle length in middle aged women. Eur J Epidemiol 15:809–814CrossRefPubMed

34.

Gerber M (1997) Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst 89:661–662CrossRefPubMed

35.

Morris PG, Hudis CA, Giri D et al (2011) Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res 4:1021–1029. doi:10.1158/1940-6207.CAPR-11-0110 CrossRef

36.

Calle EE, Kaaks R (2004) Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4:579–591. doi:10.1038/nrc1408 CrossRefPubMed

37.

Del Giudice ME, Fantus IG, Ezzat S et al (1998) Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 47:111–120CrossRefPubMed

38.

Schernhammer ES, Holly JM, Pollak MN, Hankinson SE (2005) Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomark Prev 14:699–704. doi:10.1158/1055-9965.EPI-04-0561 CrossRef

39.

Schernhammer ES, Holly JM, Hunter DJ et al (2006) Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 13:583–592. doi:10.1677/erc.1.01149 CrossRefPubMed

40.

Howlader N, Altekruse SF, Li CI et al (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. doi:10.1093/jnci/dju055 PubMedPubMedCentral

41.

Amirikia KC, Mills P, Bush J, Newman LA (2011) Higher population-based incidence rates of triple-negative breast cancer among young African-American women : implications for breast cancer screening recommendations. Cancer 117:2747–2753. doi:10.1002/cncr.25862 CrossRefPubMedPubMedCentral

42.

Flegal KM, Carroll MD, Kit BK, Ogden CL (2012) Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 307:491–497. doi:10.1001/jama.2012.39 CrossRefPubMed

43.

Begg CB, Zhang ZF (1994) Statistical analysis of molecular epidemiology studies employing case-series. Cancer Epidemiol Biomark Prev 3:173–175

Title: Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer
Authors: Lu Chen
Linda S. Cook
Mei-Tzu C. Tang
Peggy L. Porter
Deirdre A. Hill
Charles L. Wiggins
Christopher I. Li
Publication date: 01-06-2016
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-016-3825-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

A single-center, randomized, parallel controlled study comparing the efficacy and safety aspects of three anthracycline-based regimens as neoadjuvant chemotherapy in primary breast cancer

Great tumour burden in the axilla may influence lymphatic drainage in breast cancer patients

Long-term consequences of ovarian ablation for premenopausal breast cancer

Validation of an oligo-gene signature for the prognostic stratification of ductal carcinoma in situ (DCIS)

Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry

Racial disparities in individual breast cancer outcomes by hormone-receptor subtype, area-level socio-economic status and healthcare resources

Keynote webinar | Spotlight on antibody–drug conjugates in cancer